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1. INTRODUCTION {#cam42399-sec-0006}
===============

Persistent infection with oncogenic human papillomavirus (HPV) types has been recognized as an essential cause of cervical cancer and precancer.[1](#cam42399-bib-0001){ref-type="ref"}, [2](#cam42399-bib-0002){ref-type="ref"}, [3](#cam42399-bib-0003){ref-type="ref"} Cervical cancer is a major public health concern in China, with almost 100 000 cases and over 30 000 deaths estimated in 2015.[4](#cam42399-bib-0004){ref-type="ref"} In women aged 15‐44 years, it is the second most common cancer and the third most common cause of cancer‐related death in China.[5](#cam42399-bib-0005){ref-type="ref"} Overall HPV prevalence in the general population is 17.7%, according to a pooled analysis of 17 population‐based studies,[6](#cam42399-bib-0006){ref-type="ref"} with the first peak of infection with oncogenic HPV types occurring in women 15‐19 years of age.[7](#cam42399-bib-0007){ref-type="ref"} Common with worldwide data, HPV‐16 and HPV‐18 are the most prevalent HPV types associated with cervical cancer in China.[5](#cam42399-bib-0005){ref-type="ref"}

All sexually active women are at risk of HPV infection, and it is therefore important that prophylactic HPV vaccination programs target girls before they begin sexual activity. In a cross‐sectional epidemiological survey across urban and rural areas of China, there was a trend towards earlier sexual debut (median 17 years) and riskier sexual behaviors in younger cohorts of Chinese women.[8](#cam42399-bib-0008){ref-type="ref"} HPV vaccination for girls before they begin sexual activity would likely contribute to the prevention of HPV infection and associated disease in China, as has been demonstrated in other countries.[9](#cam42399-bib-0009){ref-type="ref"}, [10](#cam42399-bib-0010){ref-type="ref"}, [11](#cam42399-bib-0011){ref-type="ref"}

The AS04‐HPV‐16/18 vaccine (*Cervarix*, GSK) is licensed in over 135 countries and was approved in China in July 2016 for use in females 9‐25 years of age. The licence was extended for use in females 9‐45 years of age in May 2018. The vaccine has been shown to offer protection against infection, cytological abnormalities and cervical intraepithelial neoplasia (CIN) associated with HPV‐16/18, including CIN grade 3 or worse, the closest surrogate endpoint to cervical cancer.[12](#cam42399-bib-0012){ref-type="ref"}, [13](#cam42399-bib-0013){ref-type="ref"}, [14](#cam42399-bib-0014){ref-type="ref"}, [15](#cam42399-bib-0015){ref-type="ref"}, [16](#cam42399-bib-0016){ref-type="ref"}, [17](#cam42399-bib-0017){ref-type="ref"}, [18](#cam42399-bib-0018){ref-type="ref"} Cross‐protection against nonvaccine types has also been reported.[14](#cam42399-bib-0014){ref-type="ref"}, [19](#cam42399-bib-0019){ref-type="ref"}, [20](#cam42399-bib-0020){ref-type="ref"}, [21](#cam42399-bib-0021){ref-type="ref"} Sustained antibody responses have been demonstrated almost 10 years postvaccination,[22](#cam42399-bib-0022){ref-type="ref"} and the vaccine has an acceptable safety profile.[12](#cam42399-bib-0012){ref-type="ref"}, [23](#cam42399-bib-0023){ref-type="ref"}

Here we report the end‐of‐study analysis up to 72 months of follow‐up of a phase II/III trial in Chinese women aged 18‐25 years. The results of two previous event‐triggered analyses, with follow‐up up to 57 months following first vaccination, have been reported.[24](#cam42399-bib-0024){ref-type="ref"}, [25](#cam42399-bib-0025){ref-type="ref"} This is the first large RCT with the longest follow‐up of vaccine efficacy in the prevention of HPV infection and related cervical precancer in China. We also present data from exploratory analyses not previously reported evaluating efficacy of the vaccine against CIN irrespective of HPV type.

2. MATERIALS AND METHODS {#cam42399-sec-0007}
========================

2.1. Study design and participants {#cam42399-sec-0008}
----------------------------------

Details of the study design and participants have been published previously.[24](#cam42399-bib-0024){ref-type="ref"}, [26](#cam42399-bib-0026){ref-type="ref"} This randomized, controlled, double‐blind study evaluated the efficacy, safety and immunogenicity of the AS04‐HPV‐16/18 vaccine in healthy Chinese women aged 18‐25 years. The trial was conducted in accordance with the Declaration of Helsinki (1996) and the International Conference on Harmonisation Good Clinical Practice guidelines, and the protocol and informed consent form were approved by the ethics committees of the Center for Disease Control and Prevention (CDC) Jiangsu Province and the Cancer Foundation of China. All participants provided written informed consent. The study is registered with <http://ClinicalTrials.gov>, number NCT00779766.

Women were enrolled at four sites in Jiangsu province. All women living in the areas covered by the study sites who met the eligibility criteria were invited to participate. Women who were pregnant or breastfeeding, or had chronic or autoimmune disease under treatment or immunodeficiency were excluded. Full inclusion and exclusion criteria have been described previously.[24](#cam42399-bib-0024){ref-type="ref"}, [26](#cam42399-bib-0026){ref-type="ref"} The vaccine or control was administered in a three‐dose schedule (0, 1 and 6 months). The initial study was scheduled for 24 months, with an optional extension to 48 months and a second optional extension to 72 months. Study visits were scheduled for each participant at Months 0, 1, 6, 7, 12, 18 and 24. Visits at Months 30, 36, 42 and 48 were scheduled for women who took part in the first extension. Women who took part in the second extension had 2 or 3 further visits, depending on the time of their enrolment, at Months 60, 66 and 72.

Women were randomized 1:1 to receive either the AS04‐HPV‐16/18 vaccine or control (aluminium hydroxide), which were supplied in identical prefilled syringes. A randomization list was generated by the study sponsor using a standard Statistical Analysis System (SAS) program. A randomization blocking scheme was used to ensure balance between treatments. Treatment allocation was performed at the investigator\'s site using a central randomization system on internet (SBIR). The randomization algorithm used a minimization process accounting for study center. Participants, investigators, and study staff were blinded to treatment allocation and HPV DNA and serology results throughout the whole study period. The study blinding was maintained until database freeze for this end‐of‐study analysis.

2.2. Procedures {#cam42399-sec-0009}
---------------

Cervical samples were obtained every 6 months for HPV DNA and cytology testing (according to the protocol‐defined algorithm). A polymerase chain reaction (PCR) assay using specific SPF~10~ primers amplifying a 65‐nucleotide region of the HPV L1 gene was used to test cervical samples and biopsy material for HPV DNA from most known HPV types. HPV‐positive specimens were typed by reverse hybridization line probe assay (LiPA) using 28 HPV‐specific hybridization probes, which allowed detection of 14 oncogenic and 11 nononcogenic HPV types. All HPV‐positive samples were also tested using HPV‐16 specific and HPV‐18 specific PCR.[27](#cam42399-bib-0027){ref-type="ref"}

Cervical cytology was performed using the ThinPrep Pap Test (Cytec Corporation, Boxborough, USA) and samples were evaluated according to the Bethesda 2001 classification system. CIN terminology was used for reporting of histologically defined cervical lesions.[28](#cam42399-bib-0028){ref-type="ref"} Histopathology was handled centrally. Biopsy and excisional treatment specimens were reviewed by a panel of expert pathologists. Agreement from at least two panel members was required on the location and grade of the lesion. Final CIN case assignments were reviewed and agreed by an independent endpoint committee.

Antibody responses against HPV‐16 and HPV‐18 were determined using enzyme‐linked immunosorbent assay (ELISA)[29](#cam42399-bib-0029){ref-type="ref"} in the immunogenicity subset at Months 0, 7, 12, 24, 36, 48 and 72. Seropositivity was defined as an antibody titer greater than the assay cut‐off value. While monitoring the quality of the assay, a high variability was observed in the low range of assay results from unvaccinated trial participants.[30](#cam42399-bib-0030){ref-type="ref"} Therefore from Month 36, the assay cut‐off value was changed from 8 EL.U/mL to 19 EL.U/mL for HPV‐16 and from 7 EL.U/mL to 18 EL.U/mL for HPV‐18.

Serious adverse events (SAEs), new onset chronic diseases (NOCD), new onset autoimmune diseases (NOAD), medically significant conditions, pregnancy and pregnancy outcomes were recorded throughout follow‐up. Medically significant conditions were defined as: adverse events (AEs) prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that were not related to common diseases. Common diseases included: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities and injury.

2.3. Outcomes {#cam42399-sec-0010}
-------------

The primary endpoint was vaccine efficacy against a combined endpoint of 6‐month persistent infection (6MPI) with HPV‐16 and/or HPV‐18 (HPV‐16/18) and/or CIN grade 1 or worse (CIN1+) associated with HPV‐16/18. Secondary endpoints were incident infection, 6MPI, 12‐month persistent infection (12MPI), atypical squamous cells of undetermined significance or worse (ASC‐US+), CIN1+, and CIN grade 2 or worse (CIN2+), associated with HPV‐16/18 or with nonvaccine oncogenic HPV types individually or in combination. 6MPI was defined as at least two positive HPV DNA PCR assays for the same viral genotype with no negative DNA sample between, over an interval of approximately 6 months; 12MPI was defined in the same way over an interval of approximately 12 months. CIN1+ was defined as CIN1, CIN2, CIN3, adenocarcinoma in situ (AIS) or invasive cervical cancer. CIN2+ excluded CIN1. Vaccine efficacy irrespective of HPV DNA in the lesion was evaluated as an exploratory endpoint in the end‐of‐study analysis. Immunogenicity and safety endpoints were followed throughout the entire study period.

2.4. Statistical analysis {#cam42399-sec-0011}
-------------------------

We have previously published confirmatory event‐driven analyses reporting efficacy against 6MPI/CIN1+ (primary endpoint)[24](#cam42399-bib-0024){ref-type="ref"} and against CIN2+ (secondary endpoint).[25](#cam42399-bib-0025){ref-type="ref"} The end‐of‐study analysis reported here was descriptive and was intended to confirm and expand the efficacy results of the previous event‐driven analyses. The main focus of the present analysis was on vaccine efficacy against CIN2+. The sample size calculation was done for the confirmatory analyses on 6MPI/CIN1+ and CIN2+, and has been reported previously.[24](#cam42399-bib-0024){ref-type="ref"}, [25](#cam42399-bib-0025){ref-type="ref"} Efficacy results are presented for a combined analysis of the initial study and the two optional extension studies. Thus, data from women who did not continue to the first or second extension study are nevertheless included in the end‐of‐study analysis up to the point at which they withdrew.

The according‐to‐protocol cohort for efficacy (ATP‐E) was the primary efficacy analysis cohort, comprising women with available efficacy data, who met all eligibility criteria, received three doses of vaccine or control, complied with the protocol and had normal or low‐grade cytology (ASC‐US or low‐grade squamous intraepithelial lesions) at baseline. Efficacy analyses were also conducted in the total vaccinated cohort for efficacy (TVC‐E), comprising women with available efficacy data, who received at least one dose of vaccine or control and had normal or low‐grade cytology at baseline, and in the TVC‐naïve, comprising women with available efficacy data, who received at least one dose of vaccine or control and at baseline were HPV DNA‐negative for all 14 oncogenic types tested, seronegative for HPV‐16 and HPV‐18 and had negative cytology. The primary analysis in the ATP‐E was performed in women DNA‐negative at baseline and Month 6 and seronegative at baseline for the HPV type considered in the analysis. In the TVC‐E, the analysis was conducted in women DNA‐negative and seronegative at baseline for the type considered in the analysis. Analyses in the ATP‐E and TVC‐E were also conducted in women DNA‐negative at baseline regardless of serostatus. All women in the TVC‐naïve were DNA‐negative for all oncogenic HPV types tested and seronegative at baseline for HPV‐16 and HPV‐18.

Vaccine efficacy was calculated using a conditional exact method, which computes an exact confidence interval (CI) around the rate ratio (ratio of event rates in the vaccine vs control groups), taking into account follow‐up time within each group. Vaccine efficacy was defined as 1 minus the rate ratio. In the previously reported confirmatory analyses, statistically significant vaccine efficacy was defined as the lower limit of the 95% CI above zero.[24](#cam42399-bib-0024){ref-type="ref"}, [25](#cam42399-bib-0025){ref-type="ref"} As mentioned already, the present end‐of‐study analysis was descriptive. Follow‐up in the ATP‐E cohort started on the day after the third vaccine dose, and in the TVC‐E and TVC‐naïve on the day after the first dose, and ended for each participant at the time of the event or, if no event was reported, at the time of last data available.

Immunogenicity was primarily analyzed in the ATP cohort for immunogenicity which included women in the immunogenicity subset with available immunogenicity data, who met all eligibility criteria, received three doses of vaccine or control and complied with the protocol. Women who acquired HPV‐16 or HPV‐18 infection during the study were excluded from the ATP cohort. Seropositivity rates with exact 95% CIs and geometric mean titers (GMTs) with 95% CIs were calculated for HPV‐16 and HPV‐18. GMTs were calculated by taking the antilog of the mean of the log titer transformations. Antibody levels below the assay cut‐off value were assigned an arbitrary value of half the cut‐off for the purpose of the calculation of GMT. Safety was analyzed in the total vaccinated cohort (TVC) which included all women who received at least one dose of vaccine or control. The percentage of participants with an adverse event was calculated with exact 95% CIs. SAS version 9.2 was used for all statistical analysis.

3. RESULTS {#cam42399-sec-0012}
==========

3.1. Study participants {#cam42399-sec-0013}
-----------------------

The first woman was enrolled in October 2008. Final data were collected in February 2016. Of 6051 women enrolled in the initial study, 5430 consented to participate in the first extension up to month 48, and 4666 women consented to participate in the second extension up to month 72 (2319 vaccine, 2347 control) (Figure [1](#cam42399-fig-0001){ref-type="fig"}). For the combined end‐of‐study analysis of the initial and two extension studies reported here, the TVC included 3026 women in the vaccine group and 3025 women in the control group. The TVC‐E included 98.7% of participants, and the ATP‐E included 95.5%. Full participant disposition is shown in Figure [1](#cam42399-fig-0001){ref-type="fig"}. The mean follow‐up time after the first dose in the TVC was approximately 62 months. In the ATP‐E, follow‐up began after the third dose, with a mean of approximately 57 months. Mean age at vaccination was 23 years in both study groups; the median age was 23 years (range 18‐32) in the vaccine group and 23 years (range 18‐39) in the control group of the TVC cohort. All women were of Chinese heritage. Further details of baseline characteristics have been reported previously.[26](#cam42399-bib-0026){ref-type="ref"}

![Participant disposition. The TVC‐naïve included 1660 women in the vaccine group and 1587 women in the control group. AE, adverse event; ATP‐E, according to protocol cohort for efficacy; N, number of women in the analysis; n, number of cases; SAE, serious adverse event; TVC‐E, total vaccinated cohort for efficacy; TVC‐naïve, total vaccinated naïve cohort; TVC, total vaccinated cohort](CAM4-8-6195-g001){#cam42399-fig-0001}

3.2. Vaccine efficacy {#cam42399-sec-0014}
---------------------

### 3.2.1. Vaccine efficacy against HPV‐16/18 {#cam42399-sec-0015}

In the ATP‐E cohort in women seronegative at baseline, two cases of the primary endpoint, 6MPI/CIN1+ associated with HPV‐16/18, were reported in the vaccine group and 69 cases in the control group, resulting in a vaccine efficacy of 97.1% (95% CI: 89.1, 99.7) (Table [1](#cam42399-tbl-0001){ref-type="table"}). Vaccine efficacy was 97.8% (95% CI: 91.9, 99.7) in the ATP‐E regardless of serostatus, 94.3% (95% CI: 86.1, 98.2) in the TVC‐E in women seronegative at baseline, 93.8% (95% CI: 86.9, 97.6) in the TVC‐E regardless of serostatus, and 96.5% (95% CI: 86.9, 99.6) in the TVC‐naïve (Table [1](#cam42399-tbl-0001){ref-type="table"}). High vaccine efficacy against the secondary endpoints, incident infection, 6MPI, 12MPI and ASC‐US+, was also observed (Table [1](#cam42399-tbl-0001){ref-type="table"}).

###### 

Vaccine efficacy against endpoints associated with HPV‐16/18

                                                                                                                                                                                          Vaccine   Control   Vaccine efficacy, % (95% CI)         
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------- --------- ------------------------------ ----- -------------------
  ATP‐E, women HPV‐16/18[a](#cam42399-note-0004){ref-type="fn"} DNA‐negative at baseline and Month 6, and seronegative for HPV‐16/18[a](#cam42399-note-0004){ref-type="fn"} at baseline                                                            
  6MPI/CIN1+                                                                                                                                                                              2523      2         2534                           69    97.1 (89.1, 99.7)
  Incident infection                                                                                                                                                                      2524      34        2534                           156   78.4 (68.5, 85.5)
  6MPI                                                                                                                                                                                    2483      2         2492                           63    96.8 (88.0, 99.6)
  12MPI                                                                                                                                                                                   2428      1         2458                           32    96.9 (81.2, 99.9)
  ASC‐US+                                                                                                                                                                                 2521      5         2534                           60    91.6 (79.4, 97.4)
  CIN1+                                                                                                                                                                                   2523      1         2534                           15    93.3 (56.2, 99.8)
  CIN2+                                                                                                                                                                                   2523      1         2534                           8     87.3 (5.5, 99.7)
  ATP‐E, women HPV‐16/18[a](#cam42399-note-0004){ref-type="fn"} DNA‐negative at baseline and Month 6, regardless of initial serostatus                                                                                                             
  6MPI/CIN1+                                                                                                                                                                              2804      2         2801                           91    97.8 (91.9, 99.7)
  Incident infection                                                                                                                                                                      2806      49        2801                           204   76.5 (67.8, 83.2)
  6MPI                                                                                                                                                                                    2762      2         2748                           83    97.6 (91.1, 99.7)
  12MPI                                                                                                                                                                                   2702      1         2709                           38    97.4 (84.5, 99.9)
  ASC‐US+                                                                                                                                                                                 2802      12        2801                           83    85.7 (73.6, 92.9)
  CIN1+                                                                                                                                                                                   2804      1         2801                           18    94.4 (64.8, 99.9)
  CIN2+                                                                                                                                                                                   2804      1         2801                           10    90.0 (29.5, 99.8)
  TVC‐E, women DNA‐negative and seronegative for HPV‐16/18[a](#cam42399-note-0004){ref-type="fn"} at baseline                                                                                                                                      
  6MPI/CIN1+                                                                                                                                                                              2567      5         2587                           87    94.3 (86.1, 98.2)
  Incident infection                                                                                                                                                                      2610      49        2639                           184   73.5 (63.6, 81.1)
  6MPI                                                                                                                                                                                    2551      4         2571                           80    95.0 (86.7, 98.7)
  12MPI                                                                                                                                                                                   2518      3         2536                           41    92.6 (76.9, 98.5)
  ASC‐US+                                                                                                                                                                                 2563      7         2585                           71    90.1 (78.5, 96.2)
  CIN1+                                                                                                                                                                                   2567      2         2587                           17    88.1 (49.7, 98.7)
  CIN2+                                                                                                                                                                                   2567      1         2587                           9     88.7 (18.5, 99.7)
  TVC‐E, women HPV‐16/18[a](#cam42399-note-0004){ref-type="fn"} DNA‐negative at baseline, regardless of initial serostatus                                                                                                                         
  6MPI/CIN1+                                                                                                                                                                              2853      7         2857                           112   93.8 (86.9, 97.6)
  Incident infection                                                                                                                                                                      2900      71        2914                           238   70.8 (61.8, 77.9)
  6MPI                                                                                                                                                                                    2835      5         2839                           103   95.2 (88.5, 98.5)
  12MPI                                                                                                                                                                                   2801      4         2795                           50    92.0 (78.3, 97.9)
  ASC‐US+                                                                                                                                                                                 2849      14        2855                           97    85.7 (74.8, 92.4)
  CIN1+                                                                                                                                                                                   2853      3         2857                           21    85.7 (52.0, 97.3)
  CIN2+                                                                                                                                                                                   2853      2         2857                           12    83.3 (24.8, 98.2)
  TVC‐naïve, women DNA‐negative for all oncogenic HPV types tested and seronegative for HPV‐16 and 18 at baseline                                                                                                                                  
  6MPI/CIN1+                                                                                                                                                                              1591      2         1530                           55    96.5 (86.9, 99.6)
  Incident infection                                                                                                                                                                      1616      32        1558                           114   73.5 (60.4, 82.7)
  6MPI                                                                                                                                                                                    1588      2         1527                           52    96.3 (86.1, 99.6)
  12MPI                                                                                                                                                                                   1572      1         1507                           29    96.7 (80.1, 99.9)
  ASC‐US+                                                                                                                                                                                 1591      5         1530                           46    89.6 (73.9, 96.8)
  CIN1+                                                                                                                                                                                   1591      0         1530                           10    100 (56.9, 100)
  CIN2+                                                                                                                                                                                   1591      0         1530                           6     100 (17.9, 100)

Abbreviations: 6MPI, 6‐month persistent infection; 12MPI, 12‐month persistent infection; ASC‐US+, atypical squamous cells of undetermined significance or worse; ATP‐E, according to protocol cohort for efficacy; CI, confidence interval; CIN1+, cervical intraepithelial neoplasia grade 1 or worse; CIN2+, cervical intraepithelial neoplasia grade 2 or worse; HPV, human papillomavirus; N, number of women in analysis; n, number of cases; TVC‐E, total vaccinated cohort for efficacy; TVC‐naïve, total vaccinated naïve cohort.

For the corresponding type considered in the analysis.

John Wiley & Sons, Ltd

New HPV infections continued to accrue throughout the study. At the month 24 analysis (initial study) in the ATP‐E cohort seronegative at baseline for HPV‐16/18, one case of 6MPI/CIN1+ associated with HPV‐16/18 was detected among 2497 women in the vaccine group and 17 cases among 2502 women in the control group.[24](#cam42399-bib-0024){ref-type="ref"} This compares with two cases among 2523 women in the vaccine group and 69 cases among 2534 women in the control group at the end‐of‐study analysis (combined data from the initial study and the two extension studies). Corresponding values for incident infection were 15/2497 (vaccine), 49/2502 (control) at month 24,[24](#cam42399-bib-0024){ref-type="ref"} compared with 34/2524 (vaccine) and 156/2534 (control) at the end of study. Likewise for ASC‐US, values were 1/2494 (vaccine) and 16/2502 (control) at month 24,[24](#cam42399-bib-0024){ref-type="ref"} vs 5/2521 (vaccine) and 60/2534 (control) at the end of study.

A key focus of the end‐of‐study analysis was efficacy against CIN2+. Vaccine efficacy against CIN2+ associated with HPV‐16/18 was 87.3% (95% CI: 5.5, 99.7) in the ATP‐E in women DNA‐negative at months 0, 6 and seronegative at baseline for the corresponding type, 90.0% (95% CI: 29.5, 99.8) in the ATP‐E in women DNA‐negative regardless of initial serostatus, 88.7% (95% CI: 18.5, 99.7) in the TVC‐E in women DNA‐negative and seronegative for the corresponding type at baseline, 83.3% (95% CI: 24.8, 98.2) in the TVC‐E in women DNA‐negative at baseline regardless of initial serostatus and 100% (95% CI: 17.9, 100) in the TVC‐naïve in women DNA‐negative and seronegative for HPV‐16/18 at baseline (Table [1](#cam42399-tbl-0001){ref-type="table"}).Fourteen cases (two cases in the vaccine group and 12 in the control group) of CIN2+ associated with HPV‐16/18 were seen in the TVC‐E in women DNA‐negative at baseline regardless of serostatus (Figure [2](#cam42399-fig-0002){ref-type="fig"}).

![Clinical diagnosis and biopsy PCR results of CIN2+ cases associated with HPV‐16/18 (TVC‐E). Cases were from women in the TVC‐E who were HPV‐16/18 DNA‐negative at baseline regardless of initial serostatus. ‖Case 1 was also part of the ATP‐E cohort. \*All samples taken by punch biopsy except case 9 which was taken by endocervical curettage. CIN1, cervical intraepithelial neoplasia grade 1; CIN2, cervical intraepithelial neoplasia grade 2; CIN3, cervical intraepithelial neoplasia grade 3; HPV, human papillomavirus; LSIL, low‐grade squamous intraepithelial lesion; PCR, polymerase chain reaction; TVC‐E, total vaccinated cohort for efficacy](CAM4-8-6195-g002){#cam42399-fig-0002}

The first CIN2+ case in the vaccine group (case 1) was a woman who was also included in the ATP‐E cohort. The woman was identified with a CIN3 associated with HPV‐16 at Month 36. At baseline, she was seropositive for HPV‐18 (but seronegative for HPV‐16, the type identified in the lesion) and had normal cytology. She had an infection with HPV‐16, HPV‐51 and HPV‐52 at Month 12, and had ASC‐US associated with HPV‐16 and HPV‐52 at Month 36. Assessment of causality was difficult due to multiple oncogenic HPV infections detected in both the lesion and the preceding cytological specimens. The second woman with CIN2+ in the vaccine group (case 2) was included in the TVC‐E (but not in the ATP‐E), and was seropositive for HPV‐16 and had ASC‐US associated with HPV‐52 at baseline. She was diagnosed with CIN3 associated with HPV‐16 at Month 6; she was also identified with infection with HPV‐33 at Months 6, 12 and 18. No new CIN2+ cases were reported between the previous event‐triggered analysis[25](#cam42399-bib-0025){ref-type="ref"} and this end‐of‐study analysis.

### 3.2.2. Vaccine efficacy against nonvaccine types {#cam42399-sec-0016}

The analysis was performed in women DNA‐negative at baseline for the HPV type considered in the analysis, regardless of initial HPV‐16/18 serostatus. Women in the ATP‐E analysis were also DNA‐negative at Month 6 for the HPV type considered. Vaccine efficacy against virological endpoints associated with nonvaccine HPV types in the ATP‐E and TVC‐E is shown in Table [2](#cam42399-tbl-0002){ref-type="table"}. In the ATP‐E cohort, vaccine efficacy was observed against incident infection with HPV‐31 (59.6% \[95% CI: 39.4, 73.5\]), HPV‐33 (42.7% \[95% CI: 15.6, 61.6\]) and HPV‐45 (54.8% \[95% CI: 19.3, 75.6\]), and against 6MPI and 12MPI associated with HPV‐31 (64.6% \[95% CI: 27.6, 83.9\] and 81.3% \[95% CI: 34.5, 96.5\], respectively) (Table [2](#cam42399-tbl-0002){ref-type="table"}). Similar values were observed in the TVC‐E cohort (Table [2](#cam42399-tbl-0002){ref-type="table"}).

###### 

Vaccine efficacy against virological endpoints and ASC‐US+ associated with nonvaccine HPV types

                       ATP‐E, women DNA‐negative for HPV type considered at baseline and Month 6, regardless of HPV‐16/18 serostatus   TVC‐E, women DNA‐negative for HPV type considered at baseline, regardless of HPV‐16/18 serostatus                                                                    
  -------------------- --------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ------ ----- ------------------------ ------ ----- ------ ------ -----------------------
  Incident infection                                                                                                                                                                                                                                                                                        
  HPV‐31               2775                                                                                                            35                                                                                                  2769   86    59.6 (39.4, 73.5)        2875   44    2897   109    59.8 (42.4, 72.3)
  HPV‐33               2768                                                                                                            43                                                                                                  2770   75    42.7 (15.6, 61.6)        2872   58    2897   94     38.2 (13.4, 56.2)
  HPV‐35               2794                                                                                                            53                                                                                                  2790   65    18.2 (−19.5, 44.2)       2890   57    2908   77     25.6 (−6.2, 48.1)
  HPV‐39               2747                                                                                                            154                                                                                                 2759   133   −17.1 (−48.8, 7.8)       2858   176   2888   164    ‐8.5 (−35.0, 12.8)
  HPV‐45               2782                                                                                                            18                                                                                                  2788   40    54.8 (19.3, 75.6)        2885   28    2908   53     46.8 (14.4, 67.6)
  HPV‐51               2741                                                                                                            166                                                                                                 2742   204   18.5 (−0.5, 34.0)        2862   202   2867   227    10.7 (−8.4, 26.5)
  HPV‐52               2655                                                                                                            251                                                                                                 2651   284   11.2 (−5.6, 25.4)        2798   315   2806   341    7.0 (−8.7, 20.5)
  HPV‐56               2771                                                                                                            104                                                                                                 2766   113   7.9 (−21.3, 30.1)        2874   118   2887   129    8.3 (−18.7, 29.2)
  HPV‐58               2760                                                                                                            83                                                                                                  2755   111   25.2 (−0.3, 44.4)        2865   96    2879   134    28.2 (6.0, 45.4)
  HPV‐59               2802                                                                                                            52                                                                                                  2873   65    20.5 (−16.3, 45.9)       2898   57    2905   77     26.2 (−5.3, 48.5)
  HPV‐66               2768                                                                                                            103                                                                                                 2751   124   17.0 (−8.6, 36.7)        2877   123   2877   145    15.1 (−8.7, 33.8)
  HPV‐68               2763                                                                                                            101                                                                                                 2771   107   5.2 (−25.7, 28.5)        2875   124   2896   125    0.1 (−29.1, 22.7)
  HPV‐31/33/45         2811                                                                                                            85                                                                                                  2810   175   52.0 (37.4, 63.4)        2904   113   2921   217    48.6 (35.1, 59.4)
  HRW‐HPV              2811                                                                                                            744                                                                                                 2811   852   13.9 (4.9, 22.0)         2904   860   2921   965    11.6 (3.0, 19.5)
  HR‐HPV               2811                                                                                                            764                                                                                                 2811   914   18.5 (10.2, 26.1)        2904   886   2921   1026   15.0 (7.0, 22.4)
  6MPI                                                                                                                                                                                                                                                                                                      
  HPV‐31               2734                                                                                                            11                                                                                                  2718   31    64.6 (27.6, 83.9)        2812   16    2824   41     60.9 (28.8, 79.5)
  HPV‐33               2725                                                                                                            16                                                                                                  2716   30    46.6 (−1.2, 72.8)        2808   25    2823   37     31.9 (−16.2, 60.7)
  HPV‐35               2750                                                                                                            19                                                                                                  2738   18    −5.9 (−113.9, 47.4)      2826   19    2834   24     20.4 (−51.5, 58.8)
  HPV‐39               2703                                                                                                            63                                                                                                  2706   50    −27.3 (−88.4, 13.6)      2794   72    2816   63     −15.7 (−64.9, 18.7)
  HPV‐45               2738                                                                                                            8                                                                                                   2737   10    19.5 (−126.6, 72.4)      2820   13    2834   17     23.0 (−68.5, 65.6)
  HPV‐51               2702                                                                                                            69                                                                                                  2688   73    4.8 (−34.1, 32.5)        2799   84    2795   86     1.8 (−34.3, 28.2)
  HPV‐52               2614                                                                                                            128                                                                                                 2606   117   −10.8 (−43.6, 14.4)      2737   165   2734   140    −19.6 (−50.9, 5.1)
  HPV‐56               2728                                                                                                            43                                                                                                  2712   41    −5.0 (−65.2, 33.2)       2810   53    2815   46     −16.0 (−76.1, 23.3)
  HPV‐58               2718                                                                                                            38                                                                                                  2703   49    22.4 (−21.0, 50.6)       2800   45    2807   60     24.8 (−12.6, 50.0)
  HPV‐59               2758                                                                                                            16                                                                                                  2730   16    0.3 (−113.1, 53.3)       2833   20    2830   22     8.9 (−74.9, 52.9)
  HPV‐66               2726                                                                                                            36                                                                                                  2697   37    3.0 (−57.8, 40.4)        2812   43    2804   41     −5.1 (−65.3, 33.1)
  HPV‐68               2723                                                                                                            32                                                                                                  2718   36    10.7 (−47.9, 46.3)       2810   45    2823   45     ‐0.7 (−55.8, 34.9)
  HPV‐31/33/45         2767                                                                                                            33                                                                                                  2756   68    51.6 (25.6, 69.1)        2839   52    2846   90     42.3 (17.9, 59.8)
  HRW‐HPV              2767                                                                                                            381                                                                                                 2757   418   8.6 (−5.2, 20.7)         2839   466   2846   487    3.5 (−9.9, 15.2)
  HR‐HPV               2767                                                                                                            382                                                                                                 2757   466   18.7 (6.7, 29.1)         2839   468   2846   542    13.9 (2.4, 24.1)
  12MPI                                                                                                                                                                                                                                                                                                     
  HPV‐31               2674                                                                                                            3                                                                                                   2679   16    81.3 (34.5, 96.5)        2779   3     2779   20     85.0 (49.3, 97.1)
  HPV‐33               2666                                                                                                            9                                                                                                   2678   9     ‐0.5 (−185.8, 64.7)      2775   13    2778   11     ‐19.2 (−193.8, 50.7)
  HPV‐35               2689                                                                                                            12                                                                                                  2698   9     ‐33.9 (−259.8, 48.2)     2792   12    2790   14     13.8 (−100.7, 63.6)
  HPV‐39               2643                                                                                                            25                                                                                                  2667   22    ‐14.8 (−113.5, 37.9)     2760   32    2772   28     ‐15.7 (−99.4, 32.5)
  HPV‐45               2677                                                                                                            5                                                                                                   2697   2     ‐152.1 (−2547.2, 58.7)   2786   7     2791   6      ‐17.6 (−323.5, 66.2)
  HPV‐51               2642                                                                                                            28                                                                                                  2650   25    ‐12.9 (−101.8, 36.6)     2767   38    2750   32     ‐19.4 (−97.3, 27.4)
  HPV‐52               2555                                                                                                            72                                                                                                  2571   65    ‐11.9 (−59.0, 21.1)      2704   98    2694   76     ‐30.5 (−78.4, 4.3)
  HPV‐56               2667                                                                                                            14                                                                                                  2675   12    ‐17.1 (−177.2, 49.7)     2776   16    2770   14     ‐15.0 (−154.3, 47.4)
  HPV‐58               2659                                                                                                            15                                                                                                  2664   18    16.5 (−75.6, 60.8)       2768   19    2764   22     13.2 (−68.0, 55.6)
  HPV‐59               2697                                                                                                            8                                                                                                   2690   2     ‐299.8 (−3764.5, 20.2)   2799   10    2785   4      ‐150.8 (−995.3, 27.7)
  HPV‐66               2665                                                                                                            17                                                                                                  2660   10    ‐70.0 (−315.6, 26.5)     2779   22    2759   13     ‐69.6 (−266.4, 18.3)
  HPV‐68               2662                                                                                                            12                                                                                                  2678   12    ‐0.7 (−144.9, 58.6)      2778   18    2779   19     4.7 (−91.8, 52.8)
  HPV‐31/33/45         2706                                                                                                            16                                                                                                  2716   27    40.6 (−14.3, 70.1)       2805   22    2801   37     40.4 (−3.7, 66.5)
  HRW‐HPV              2706                                                                                                            196                                                                                                 2717   192   ‐3.0 (−26.4, 16.0)       2805   253   2801   239    ‐7.3 (−28.6, 10.4)
  HR‐HPV               2706                                                                                                            196                                                                                                 2717   219   10.3 (−9.3, 26.4)        2805   254   2801   273    6.4 (−11.4, 21.4)
  ASC‐US+                                                                                                                                                                                                                                                                                                   
  HPV‐31               2771                                                                                                            12                                                                                                  2769   32    62.5 (25.2, 82.4)        2826   17    2839   40     57.3 (22.9, 77.3)
  HPV‐33               2764                                                                                                            17                                                                                                  2770   32    46.7 (1.1, 72.2)         2821   23    2838   37     37.3 (−8.4, 64.4)
  HPV‐35               2790                                                                                                            20                                                                                                  2790   21    4.4 (−85.4, 50.8)        2839   20    2850   24     16.1 (−58.5, 56)
  HPV‐39               2743                                                                                                            49                                                                                                  2759   35    ‐41.6 (−125.1, 10.1)     2807   56    2831   43     ‐32.1 (−101.3, 12.8)
  HPV‐45               2778                                                                                                            9                                                                                                   2788   12    24.4 (−95.4, 71.9)       2834   11    2850   15     26.0 (−72.4, 69.3)
  HPV‐51               2738                                                                                                            64                                                                                                  2742   78    17.5 (−16.3, 41.7)       2812   75    2810   87     13.5 (−19.2, 37.4)
  HPV‐52               2651                                                                                                            83                                                                                                  2651   81    ‐3.7 (−42.6, 24.6)       2749   99    2749   95     ‐5 (−40.7, 21.5)
  HPV‐56               2767                                                                                                            46                                                                                                  2766   51    9.6 (−37.4, 40.6)        2823   55    2829   55     ‐0.7 (−49.1, 32)
  HPV‐58               2756                                                                                                            36                                                                                                  2755   49    26.2 (−15.8, 53.4)       2814   42    2821   57     25.8 (−12.5, 51.4)
  HPV‐59               2798                                                                                                            20                                                                                                  2783   17    ‐17.7 (−139.2, 41.5)     2847   24    2846   23     ‐4.7 (−94.2, 43.4)
  HPV‐66               2764                                                                                                            42                                                                                                  2751   46    8.6 (−42, 41.3)          2826   48    2818   52     7.4 (−39.8, 38.8)
  HPV‐68               2759                                                                                                            30                                                                                                  2771   37    18.4 (−35.8, 51.3)       2824   36    2838   43     15.6 (−34.6, 47.3)
  HPV‐31/33/45         2807                                                                                                            34                                                                                                  2810   66    48.4 (20.9, 67.0)        2853   46    2862   81     43.1 (17.2, 61.2)
  HRW‐HPV              2807                                                                                                            309                                                                                                 2811   352   12.0 (−2.8, 24.7)        2853   354   2862   394    9.7 (−4.5, 22.0)
  HR‐HPV               2807                                                                                                            313                                                                                                 2811   386   19.2 (6.0, 30.6)         2853   357   2862   431    17.3 (4.6, 28.3)

For combined types, women were DNA‐negative at baseline (ATP‐E and TVC‐E) and Month 6 (ATP‐E) for at least one of the HPV types considered in the analysis. Women could be infected with multiple HPV types. Therefore, the number of cases for combined types (HPV‐31/33/45, HRW‐HPV and HR‐HPV) might not equal the sum of the cases for each individual type included in the composite.

Abbreviation: 6MPI, 6‐month persistent infection; 12MPI, 12‐month persistent infection; ASC‐US+, atypical squamous cells of undetermined significance or worse; ATP‐E, according to protocol cohort for efficacy; CI, confidence interval; HPV, human papillomavirus; HR‐HPV, any oncogenic HPV type including HPV‐16 or HPV‐18; HRW‐HPV, any oncogenic HPV type except HPV‐16 and HPV‐18; N, number of women in analysis; n, number of cases; TVC‐E, total vaccinated cohort for efficacy.
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In addition, vaccine efficacy was observed against ASC‐US+ associated with HPV‐31 (62.5% \[95% CI: 25.2, 82.4\]) and HPV‐33 (46.7% \[95% CI: 1.1, 72.2\]) in the ATP‐E; efficacy was similar in the TVC‐E but the lower limit of the 95% CI was below zero for HPV‐33 (Table [2](#cam42399-tbl-0002){ref-type="table"}). Vaccine efficacy in the ATP‐E against HPV‐31/33/45‐associated CIN1+ was 36.1% (95% CI: −80.5, 79.0), with seven cases in the vaccine group and 11 cases in the control group (Supporting information Table [S1](#cam42399-sup-0001){ref-type="supplementary-material"}); vaccine efficacy against HPV‐31/33/45‐associated CIN2+ was 74.9% (95% CI: −25.8, 97.4), with three cases in the vaccine group and 18 cases in the control group (Supporting information Table [S1](#cam42399-sup-0001){ref-type="supplementary-material"}). Number of cases of CIN2+ associated with HPV‐31 occurred in the vaccine group compared with four cases in the control group (vaccine efficacy: 100% \[95% CI: −51.9, 100\]) (Supporting information Table [S1](#cam42399-sup-0001){ref-type="supplementary-material"}).

### 3.2.3. Vaccine efficacy irrespective of HPV DNA in the lesion {#cam42399-sec-0017}

Vaccine efficacy against CIN2+ irrespective of HPV DNA in the lesion was assessed in the TVC‐naïve. A total of 27 CIN2+ cases was observed at the end of the study, 11 in the vaccine group and 16 in the control group, resulting in a vaccine efficacy point estimate of 33.5% (95% CI: −52.6, 72.1). None of the cases in the vaccine group was associated with HPV‐16/18 (Figure [3](#cam42399-fig-0003){ref-type="fig"}). The most frequent nonvaccine types associated with CIN2+ in the vaccine group were HPV‐58, −33, −39, −35, and −52 (Figure [3](#cam42399-fig-0003){ref-type="fig"}). Six cases of CIN3+ were observed, two in the vaccine group and four in the control group (Figure [3](#cam42399-fig-0003){ref-type="fig"}). HPV‐39 and −58 were associated with the two cases of CIN3+ observed in the vaccine group.

![Number of cases of CIN2+ and CIN3+ associated with vaccine and nonvaccine types (TVC‐naïve). The incidence rate of CIN2+ irrespective of HPV was 0.13 per 100 person‐years in the vaccine group and 0.20 per 100 person‐years in the control group. The incidence rate of CIN3+ irrespective of HPV was 0.02 per 100 person‐years in the vaccine group and 0.05 per 100 person‐years in the control group. Oncogenic HPV types detected in CIN2+ cases in the vaccine group: no HPV detected (n = 2); HPV‐33 (n = 2); HPV‐35 (n = 1); HPV‐39 (n = 2); HPV‐51 (n = 1); HPV‐52/58 (n = 1); HPV‐58 (n = 1); HPV‐58/66 (n = 1). Oncogenic HPV types detected in CIN2+ cases in the control group: HPV‐16 (n = 4); HPV‐16/31/39 (n = 1); HPV‐16/66 (n = 1); HPV‐33 (n = 3); HPV‐35 (n = 1); HPV‐35/52 (n = 1); HPV‐45 (n = 1); HPV‐52 (n = 1); HPV‐58 (n = 3). Oncogenic HPV types detected in CIN3+ cases in the vaccine group: HPV‐58 (n = 1); HPV‐39 (n = 1). Oncogenic HPV types detected in CIN3+ cases in the control group: HPV‐16 (n = 2); HPV‐16/31/39 (n = 1); HPV‐58 (n = 1) CIN2+: cervical intraepithelial neoplasia grade 2 or worse. CIN3+, cervical intraepithelial neoplasia grade 3 or worse; HPV, human papillomavirus; TVC‐naïve, total vaccinated naïve cohort](CAM4-8-6195-g003){#cam42399-fig-0003}

3.3. Immunogenicity {#cam42399-sec-0018}
-------------------

Immunogenicity against HPV‐16 and HPV‐18 was sustained throughout the study (Figure [4](#cam42399-fig-0004){ref-type="fig"}). Seropositivity at Month 72 was \>95% for both HPV‐16 and HPV‐18 antibodies in initially seronegative women who received the HPV vaccine. GMTs were 678.1 EL.U/mL (95% CI: 552.9, 831.5) for HPV‐16 and 343.7 EL.U/mL (95% CI: 291.9, 404.8) for HPV‐18 at Month 72.

![Immunogenicity in initially seronegative women receiving the HPV‐16/18 vaccine (ATP cohort for immunogenicity). Numbers above bars show the percentage seropositivity. Solid line shows the level of antibodies observed following clearance of a natural infection ie GMTs observed in women who were HPV‐16/18 DNA‐negative and seropositive at baseline in a phase III efficacy study (29.8 EL.U/mL for HPV‐16 and 22.6 EL.U/mL for HPV‐18).[34](#cam42399-bib-0034){ref-type="ref"} ATP, according to protocol; CI, confidence interval; EL.U, ELISA units; GMT, geometric mean titer; HPV, human papillomavirus; M, month; Pre, prevaccination](CAM4-8-6195-g004){#cam42399-fig-0004}

3.4. Safety {#cam42399-sec-0019}
-----------

Reactogenicity and adverse events following AS04‐HPV‐16/18 vaccine administration in this study have been reported previously.[24](#cam42399-bib-0024){ref-type="ref"} Safety and pregnancy outcomes are shown in Table [3](#cam42399-tbl-0003){ref-type="table"}. SAEs were reported in 56 women in the vaccine group and in 81 women in the control group; the most common event was appendicitis, reported in four women in the vaccine group and 12 in the control group. One SAE was considered by the investigator to be possibly related to vaccination: a gastrointestinal tract reaction following vaccination in a woman receiving control vaccine. Three women in the control group died, one with a recorded cause of gastric neoplasm and two through suicide. No deaths were considered related to vaccination. No women in the vaccine group died. A medically significant condition was reported in 186 (6.1%) and 185 (6.1%) women in the vaccine and control groups, respectively. NOCDs and NOADs were rare and none was considered related to vaccination (Table [3](#cam42399-tbl-0003){ref-type="table"}).

###### 

Safety and pregnancy outcomes throughout study (TVC)

                                                                                                              No. (%) women reporting outcome   
  ----------------------------------------------------------------------------------------------------------- --------------------------------- ------------
  Safety outcomes                                                                                                                               
  Serious adverse event[a](#cam42399-note-0008){ref-type="fn"}                                                56 (1.9)                          81 (2.7)
  Medically significant condition[b](#cam42399-note-0009){ref-type="fn"}                                      186 (6.1)                         185 (6.1)
  New onset chronic disease[c](#cam42399-note-0010){ref-type="fn"}, [d](#cam42399-note-0011){ref-type="fn"}   9 (0.3)                           12 (0.4)
  Hyperthyroidism                                                                                             0                                 1 (0.0)
  Allergy to arthropod bite                                                                                   0                                 1 (0.0)
  Anaphylactic reaction                                                                                       1 (0.0)                           0
  Hypersensitivity                                                                                            1 (0.0)                           1 (0.0)
  Arthritis                                                                                                   0                                 1 (0.0)
  Gestational diabetes                                                                                        0                                 1 (0.0)
  Dermatitis allergic                                                                                         3 (0.1)                           4 (0.1)
  Dermatitis atopic                                                                                           1 (0.0)                           0
  Dermatitis contact                                                                                          0                                 1 (0.0)
  Psoriasis                                                                                                   1 (0.0)                           1 (0.0)
  Urticaria                                                                                                   2 (0.1)                           2 (0.1)
  New onset autoimmune disease[c](#cam42399-note-0010){ref-type="fn"}                                         2 (0.1)                           2 (0.1)
  Hyperthyroidism                                                                                             0                                 1 (0.0)
  VIIth nerve paralysis                                                                                       1 (0.0)                           0
  Psoriasis                                                                                                   1 (0.0)                           1 (0.0)
  Deaths                                                                                                      0                                 3
  Pregnancy outcomes                                                                                                                            
  Number of pregnancies                                                                                       837                               853
  Live infant with no congenital abnormality                                                                  648 (77.4)                        657 (77.0)
  Live infant with congenital anomaly[e](#cam42399-note-0012){ref-type="fn"}                                  5 (0.6)                           0
  Spontaneous abortion[f](#cam42399-note-0013){ref-type="fn"}                                                 16 (1.9)                          13 (1.5)
  Elective termination, no congenital anomaly                                                                 139 (16.6)                        158 (18.5)
  Elective termination, with congenital anomaly[g](#cam42399-note-0014){ref-type="fn"}                        1 (0.1)                           2 (0.2)
  Ectopic pregnancy                                                                                           7 (0.8)                           7 (0.8)
  Stillbirth, no congenital anomaly                                                                           0                                 2 (0.2)
  Stillbirth, with congenital anomaly[h](#cam42399-note-0015){ref-type="fn"}                                  0                                 1 (0.1)
  Lost to follow‐up                                                                                           20 (2.4)                          13 (1.5)

Abbreviations: IDMC, Independent Data Monitoring Committee; N, number of women; NOAD, new onset autoimmune disease; NOCD, new onset chronic disease; TVC, total vaccinated cohort.

Serious adverse events were defined as any untoward medical occurrence that results in death, is life‐threatening, requires hospitalization or prolongs hospitalization, results in disability or incapacity, or congenital anomaly or birth defect in the offspring of a study subject.

Medically significant conditions were defined as adverse events prompting either emergency room visits, physician visits that are not routine or related to common diseases, or serious adverse events that are not related to common diseases.

A predefined list of potential NOCDs was reviewed by the IDMC. Based on this prespecified list, the clinical database was searched for all potential NOCDs and reviewed in a blind manner by a GlaxoSmithKline physician prior to data analysis. An event was considered to be a potential NOCD if it had not been recorded in the previous medical history of the woman (ie new onset) and/or if symptoms were characteristic of an NOCD. A separate list, restricted to potential autoimmune events, was also reviewed by the IDMC and was used by the GlaxoSmithKline safety physician to identify NOADs.

One woman in the control group experienced two symptoms: allergy to arthropod bite and dermatitis allergic.

Congenital anomalies were defined as structural‐morphological, chromosomal and genetic anomalies. Anomalies observed were cleft lip and palate (two infants), muscular torticollis (two infants) and foramen ovale patent (one infant).

No congenital anomalies were identified among the spontaneous abortions.

Down\'s Syndrome (vaccine group), hydrocephalus and achondroplasia (control group).

Papyraceous fetus.

John Wiley & Sons, Ltd

A total of 837 and 853 pregnancies were recorded in the vaccine and control groups, respectively (Table [3](#cam42399-tbl-0003){ref-type="table"}). Most pregnancies (77%) resulted in live infants with no congenital anomalies; 18% of women had an elective termination. Three infants were stillborn, all in the control group. Nine congenital anomalies were reported, five in liveborn infants in the vaccine group (two with a cleft lip and palate, two with muscular torticollis and one with foramen ovale patent), one in an elective termination in the vaccine group (Down\'s Syndrome), two in elective terminations in the control group (hydrocephalus and achondroplasia), and one in a stillborn infant in the control group (papyraceous fetus) (Table [3](#cam42399-tbl-0003){ref-type="table"}). No pattern in the nature of congenital anomalies was observed and none was considered possibly related to vaccination by the investigator. Sixteen (1.9%) and 13 (1.5%) women in the vaccine and control groups, respectively, experienced a spontaneous abortion, none of which was associated with a congenital anomaly (Table [3](#cam42399-tbl-0003){ref-type="table"}).

4. DISCUSSION {#cam42399-sec-0020}
=============

Data from this study have been previously described.[24](#cam42399-bib-0024){ref-type="ref"}, [25](#cam42399-bib-0025){ref-type="ref"} Here, we report data at the end of the study with up to 6 years of follow‐up, the longest follow‐up of the efficacy of an HPV vaccine in China. We have shown high, sustained vaccine efficacy against HPV‐16/18‐associated persistent infection and cervical lesions, and noteworthy evidence of cross‐protection with the AS04‐HPV‐16/18 vaccine.

CIN2+ is the traditional surrogate efficacy endpoint used in HPV vaccine trials. Indeed, the follow‐up time of the current study was extended to 72 months after the first vaccine dose to allow further evaluation of vaccine efficacy for this endpoint. At the end of the study, a high vaccine efficacy against CIN2+ associated with HPV‐16/18 was observed in all study cohorts, with 100% vaccine efficacy in the TVC‐naïve cohort. Vaccine efficacy does not appear to be impacted in a major way by previously cleared HPV infection in the ATP cohort (ie in women regardless of initial serostatus vs seronegative for HPV‐16/18 at baseline); this has been previously shown in women who were HPV‐16/18 seropositive before vaccination.[31](#cam42399-bib-0031){ref-type="ref"}

In the two CIN2+ cases associated with HPV‐16 in the vaccine group of the TVC‐E, infections with HPV‐16, HPV‐51 and HPV‐52 were detected in one woman, and with HPV‐16 and HPV‐33 in the other woman. Although both cases were assigned as CIN2+ associated with HPV‐16 according to the HPV type assignment algorithm,[32](#cam42399-bib-0032){ref-type="ref"} definite causality could not be established. The phenomenon of coinfection with multiple oncogenic HPV types and the observed vaccine efficacy are in line with previous studies of the AS04‐HPV‐16/18 vaccine conducted in similar age groups in a wide range of countries.[12](#cam42399-bib-0012){ref-type="ref"}, [13](#cam42399-bib-0013){ref-type="ref"}, [14](#cam42399-bib-0014){ref-type="ref"}, [15](#cam42399-bib-0015){ref-type="ref"} Data from the large PATRICIA study suggest that efficacy estimates increase as time progresses[12](#cam42399-bib-0012){ref-type="ref"}, [32](#cam42399-bib-0032){ref-type="ref"}, [33](#cam42399-bib-0033){ref-type="ref"}; this is likely to be a result of continued accrual of cases in the control group, with few cases observed over time in the vaccine group. This observation is supported by data from our study which indicate that efficacy of the AS04‐HPV‐16/18 vaccine is sustained in Chinese women up to 72 months of follow‐up. Sustained vaccine efficacy has been previously reported up to nearly 10 years post vaccination in other populations.[22](#cam42399-bib-0022){ref-type="ref"}

Evaluation of cross‐protective efficacy against nonvaccine HPV types is a challenge in HPV vaccine trials.[19](#cam42399-bib-0019){ref-type="ref"} Because nonvaccine types are less common than HPV‐16 or HPV‐18, large sample size and lengthy follow‐up are usually required in order to accrue sufficient endpoint cases for statistically meaningful analysis. Most vaccine trials, including the present study, are not statistically powered to evaluate cross‐protection. Nevertheless, the study showed evidence of vaccine efficacy against incident infection with HPV‐31, HPV‐33 and HPV‐45, and against 6MPI and 12MPI with HPV‐31. These data are generally consistent with previous reports of efficacy against HPV‐31, HPV‐33 and HPV‐45.[13](#cam42399-bib-0013){ref-type="ref"}, [14](#cam42399-bib-0014){ref-type="ref"}, [16](#cam42399-bib-0016){ref-type="ref"}, [21](#cam42399-bib-0021){ref-type="ref"} However, the findings must be viewed with caution, given the caveats mentioned above and the limitations of the sample size regarding evaluation of cross‐protective efficacy. Globally, HPV‐31, HPV‐33 and HPV‐45 are among the most common types after HPV‐16 and HPV‐18, and are recognized as important causes of cervical cancer.[33](#cam42399-bib-0033){ref-type="ref"}, [34](#cam42399-bib-0034){ref-type="ref"}, [35](#cam42399-bib-0035){ref-type="ref"}, [36](#cam42399-bib-0036){ref-type="ref"} In China, HPV‐31, HPV‐33 and HPV‐45 together account for approximately 8% of cervical cancers.[5](#cam42399-bib-0005){ref-type="ref"} In addition, some epidemiology data show that HPV‐58 and HPV‐52 are the most prevalent types in Chinese women with cervical cancer after HPV‐16 and HPV‐18.[5](#cam42399-bib-0005){ref-type="ref"} In our study, vaccine efficacy against incident infection was 28.2% (95% CI: 6.0, 45.4) for HPV‐58 and 7.0% (95% CI: −8.7, 20.5) for HPV‐52 in the TVC‐E.

Vaccine efficacy against incident infection was higher than vaccine efficacy against 6MPI or 12MPI for some nonvaccine HPV types such as HPV‐45 and HPV‐58. This may be explained by a phenomenon known as masking by which infections with some nonvaccine types may have been missed by the SPF10‐LiPA assay used to genotype HPV types in this trial when HPV16 is present.[20](#cam42399-bib-0020){ref-type="ref"} Masking of nonvaccine type infections in women in the control group with multiple HPV infections may have led to a bias against the vaccine.[20](#cam42399-bib-0020){ref-type="ref"}

To explore the potential overall effect of HPV vaccination, vaccine efficacy against CIN2+ irrespective of HPV DNA in the lesion was evaluated in the TVC‐naïve, comprising women who at baseline were DNA‐negative for all 14 oncogenic HPV types tested, seronegative for HPV‐16 and HPV‐18 and had negative cytology. The analysis of the overall effect of vaccination was conducted in the TVC‐naïve because these women had no evidence of HPV infection at baseline; the HPV vaccine is a prophylactic vaccine intended to be administered to girls before HPV infection can be acquired via sexual activity. However, all subjects in the current study were enrolled after their sexual debut. Therefore, it is possible that some women included in the TVC‐naïve cohort were not truly naïve and may have preexisting HPV infection that was not detected due to constraints of sampling or the laboratory assays used. In the present study, vaccine efficacy against CIN2+ irrespective of HPV DNA in the lesion was 33.5% (95% CI: −52.6, 72.1). This compares with vaccine efficacy of 64.9% (95% CI: 52.7, 74.2) against CIN2+ irrespective of HPV DNA in the lesion in the TVC‐naïve population of the PATRICIA trial.[12](#cam42399-bib-0012){ref-type="ref"}

The observed difference of the point estimates in overall efficacy in HPV‐naïve women between the current study and PATRICIA may be explained by several factors related to sample size, study design and local HPV epidemiology. The present study enrolled approximately 6000 young women (approximately one third of the size of the PATRICIA trial sample) and was not powered to assess overall impact, which leads to a point estimate with a wide CI that includes the point estimate observed in PATRICIA.

Median age at enrolment was 23 years in the current study compared with 20 years in the PATRICIA trial. In addition, due to ethical and cultural considerations in China, only women who were already sexually active before the start of the study were enrolled in the trial, and the majority of women were already married with stable sexual relationships. Likely linked to these enrolment criteria, the incidence rates of CIN2+ irrespective of HPV in the control group of the TVC‐naïve population were very low in the current study (0.20 per 100 person‐years), more than four times lower compared with the PATRICIA trial (0.84 per 100 person‐years).[12](#cam42399-bib-0012){ref-type="ref"}

Interestingly, the incidence rate of CIN2+ irrespective of HPV types in the current study is similar to that observed in the VIVIANE trial (0.19 in 100 follow‐up years) that enrolled women 25 years and older.[16](#cam42399-bib-0016){ref-type="ref"} In that study, a similarly low efficacy irrespective of type against CIN2+ was observed (6.6% \[95% CI: −124.3, 61.4\]) in the TVC‐naïve, suggesting an impact of age and/or sexual activity at time of vaccination, in spite of negative PCR results at baseline.

Another factor worth considering in the interpretation of overall vaccine impact is related to HPV prevalence and genotype distribution in different regions. While HPV‐16/18 are the most common oncogenic types accounting for cervical cancer in China,[5](#cam42399-bib-0005){ref-type="ref"}, [37](#cam42399-bib-0037){ref-type="ref"} it was observed in the current study that less than 40% of CIN2+ cases (6 out of 16, Figure [3](#cam42399-fig-0003){ref-type="fig"}) in the control group of the TVC‐naïve was associated with HPV‐16/18 only (4 cases) or associated with HPV‐16/18 and coinfected with a nonvaccine type (2 cases). HPV types 39, 52 and 58 were detected in 6 out of 16 CIN2+ lesions in the control group, and 6 out of 11 in the vaccine group of the TVC‐naïve. Cross‐protection has not been demonstrated consistently for these types.

We observed high and sustained anti‐HPV‐16 and anti‐HPV‐18 antibody levels in Chinese women, in line with previous long‐term studies.[16](#cam42399-bib-0016){ref-type="ref"}, [22](#cam42399-bib-0022){ref-type="ref"}, [38](#cam42399-bib-0038){ref-type="ref"} Long‐term protection against HPV infection is believed to be mediated via transudation of neutralizing antibodies induced by vaccination across the cervical epithelium to the site of HPV infection.[39](#cam42399-bib-0039){ref-type="ref"}, [40](#cam42399-bib-0040){ref-type="ref"}, [41](#cam42399-bib-0041){ref-type="ref"}, [42](#cam42399-bib-0042){ref-type="ref"} Mathematical modeling based on data from a previous study predicts that anti‐HPV‐16 and anti‐HPV‐18 antibody levels will remain above those associated with natural infection for at least 20 years postvaccination.[22](#cam42399-bib-0022){ref-type="ref"} We anticipate that the high antibody levels observed up to 72 months after first vaccination in our study will be sustained in the future, providing strong and long‐term protection against HPV infection in this population.

Serious AEs and AEs of interest (eg autoimmune disorders) occurred at a similar frequency in women receiving the AS04‐HPV‐16/18 vaccine or control, and at a comparable rate to data reported in global studies of women in a similar age group.[12](#cam42399-bib-0012){ref-type="ref"}, [14](#cam42399-bib-0014){ref-type="ref"}, [22](#cam42399-bib-0022){ref-type="ref"}, [23](#cam42399-bib-0023){ref-type="ref"} No fatal events or related SAEs occurred in the AS04‐HPV‐16/18 vaccine group. Most pregnancies resulted in a normal infant or were terminated electively. Few congenital anomalies observed in these women, who had had long gap between exposure to study vaccine and their last menstrual period prior to pregnancy (0.5 to 2.7 years). No pattern in the nature of congenital anomalies was identified and none was considered related to vaccination by the investigator. No safety signal concerning congenital anomalies has arisen during the AS04‐HPV‐16/18 vaccine trials, including the large PATRICIA trial and a pooled analysis of safety data which included over 10 000 pregnancies.[12](#cam42399-bib-0012){ref-type="ref"}, [23](#cam42399-bib-0023){ref-type="ref"} Moreover, the incidence of congenital anomalies in the study was low compared with the reported incidence in the general population of China.[43](#cam42399-bib-0043){ref-type="ref"}, [44](#cam42399-bib-0044){ref-type="ref"}

Strengths and limitations of the study have been discussed previously.[24](#cam42399-bib-0024){ref-type="ref"}, [25](#cam42399-bib-0025){ref-type="ref"}

A lay language summary contextualizing the results and potential clinical research relevance and impact is displayed in Figure [5](#cam42399-fig-0005){ref-type="fig"}.
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5. CONCLUSIONS {#cam42399-sec-0021}
==============

This long‐term efficacy study showed that the AS04‐HPV‐16/18 vaccine protects young Chinese women against infection, abnormal cytology and CIN lesions associated with HPV‐16/18 up to 72 months after first vaccination. In addition, data from this study on cross‐protection against HPV‐31, HPV‐33 and HPV‐45 are generally consistent with data from other trials of the same vaccine, including the large, multinational PATRICIA trial.[19](#cam42399-bib-0019){ref-type="ref"} Immunogenicity was high and sustained throughout the trial, and the vaccine had an acceptable safety profile. Overall, the results are consistent with those of large global trials of the AS04‐HPV‐16/18 vaccine.
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